The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.K. Healthcare Workers Begin COVID-19 HCQ Trial

U.K. Healthcare Workers Begin COVID-19 HCQ Trial

May 26, 2020 • By Kylie MacLellan

  • Tweet
  • Email
Print-Friendly Version / Save PDF

LONDON (Reuters)—On May 21, British healthcare workers began taking part in a University of Oxford-led international trial of two anti-malarial drugs to see if they can prevent COVID-19, including one U.S. President Donald Trump says he has been taking.

You Might Also Like
  • HCQ Prolongs QT Interval in Patients with COVID-19
  • U.S. FDA Says HCQ & Other Malaria Drugs in Shortage as COVID-19 Drives Up Demand
  • Rheumatology in the Age of COVID-19: HCQ Shortages Driven by Small, Nonrandomized Study

The COPCOV study will involve more than 40,000 frontline healthcare workers from Europe, Africa, Asia and South America to determine if chloroquine and hydroxychloroquine (HCQ) are effective in preventing the novel coronavirus.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Demand for HCQ surged after Trump touted it in early April. Earlier last week the U.S. leader said he was now taking the drug as a preventive medicine against the virus despite medical warnings about its use.

The trial, led by the University of Oxford with the support of the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, will open to British participants at hospital sites in Brighton and Oxford on Thursday and involve those who are in close contact with patients with proven or suspected COVID-19.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We really do not know if chloroquine or HCQ are beneficial or harmful against COVID-19,” says the University of Oxford’s Prof. Nicholas White, the study’s co-principal investigator, who is based at MORU.

“The best way to find out if they are effective in preventing COVID-19 is in a randomised clinical trial.”

The COPCOV team said laboratory evidence showed the anti-malarial drugs might be effective in preventing or treating COVID-19 but there was no conclusive proof.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

U.S. regulators have authorized the emergency use of HCQ for coronavirus patients, but the U.S. Food and Drug Administration has warned against the use of it in COVID-19 patients outside of the hospital or clinical trials due to the risk of serious heart rhythm problems.

“These trials will give us the best understanding of how safe and effective these drugs might be across different populations and age groups,” says Nick Cammack, COVID-19 Therapeutics Accelerator Lead at the Wellcome Trust, a U.K.-based medical research charity which is helping to fund the trial.

“If, and only if, they are effective, these drugs can be scaled up and rolled out quickly across the world.”

In Britain, Europe and Africa, participants will receive either HCQ or a placebo for three months. In Asia, they will receive either chloroquine or a placebo.

A total of 25 study sites are expected to be open in the U.K. by the end of June, MORU said, with plans for further sites in Thailand and Southeast Asia, Italy, Portugal, Africa and South America. The results are expected by the end of this year.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, HCQ, Hydroxychloroquine (HCQ)

You Might Also Like:
  • HCQ Prolongs QT Interval in Patients with COVID-19
  • U.S. FDA Says HCQ & Other Malaria Drugs in Shortage as COVID-19 Drives Up Demand
  • Rheumatology in the Age of COVID-19: HCQ Shortages Driven by Small, Nonrandomized Study
  • Tocilizumab Begins Clinical Trial for COVID-19

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)